Andrea B. Apolo

Oct 23, 2024 | urotoday.com | Andrea B. Apolo

Read the Full Video TranscriptAshish Kamat: Hello, everyone, and welcome once again to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, and it's a distinct pleasure to welcome to this forum, once again, Professor Andrea Apolo from the NCI, who's joining us today to talk about something that she talks so well about, which is the care of patients in bladder cancer. Today, Andrea, thank you for taking the time and spending it with us today.

Sep 15, 2024 | urotoday.com | Andrea B. Apolo

Read the Full Video TranscriptZach Klaassen: Hi, my name is Zach Klaassen, a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined today by Dr. Andrea Apolo, who's a medical oncologist at the NCI. Andrea, thanks so much for joining us today. Andrea Apolo: Oh, thank you for having me.

Mar 1, 2024 | urotoday.com | Andrea B. Apolo

Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing. Patients who received pembrolizumab had a median disease-free survival of 29 months versus 14 months for the observation arm.

Feb 13, 2024 | nature.com | Chandra sekhar amara |Andrea B. Apolo |Jianjun Gao |Yair Lotan |H. Courtney Hodges |Seth P Lerner | +5 more

AbstractSMARCB1 loss has long been observed in many solid tumors. However, there is a need to elucidate targetable pathways driving growth and metastasis in SMARCB1-deficient tumors. Here, we demonstrate that SMARCB1 deficiency, defined as genomic SMARCB1 copy number loss associated with reduced mRNA, drives disease progression in patients with bladder cancer by engaging STAT3. SMARCB1 loss increases the chromatin accessibility of the STAT3 locus in vitro.

Jan 29, 2024 | bpno.dk | Andrea B. Apolo

januar 2024 Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group.